Skip to main content
. 2017 Mar 27;37(2):BSR20160445. doi: 10.1042/BSR20160445

Figure 5. PKC β overexpression up-regulates the cisplatin-induced PKC beta phosphorylation and apoptosis in Hela cells.

Figure 5

Hela cells were transfected with PKC β-pcDNA3.1(+) or CAT-pcDNA3.1(+) plasmid for 6 h and then were treated with 0 or 20 μM cisplatin for 24 h. (A) Western blotting assay for PKC β, with or without phosphorylation (T642) in the Hela cells, with or without PKC β overexpression, in the absence of presence of cisplatin. (B, C) Ratio of PKC β (B) or p-PKC β to GAPDH in the Hela cells, with or without PKC β overexpression, in the absence of presence of cisplatin; (D, E) MTT assay for the cellular viability (D) or the apoptosis induction (E) of the Hela cells, post the PKC β overexpression and cisplatin treatment. Experiments were performed independently in triplicate; ns, no significance; *P<0.05, ***P<0.001 or ****P<0.0001.